Lee Stephen, Saxinger Lynora, Ma Mang, Prado Verónica, Fernández Joaquin, Kumar Deepali, Gonzalez-Abraldes Juan, Keough Adam, Bastiampillai Ravin, Carbonneau Michelle, Fernandez Javier, Tandon Puneeta
Cirrhosis Care Clinic-Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.
Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.
United European Gastroenterol J. 2017 Dec;5(8):1090-1099. doi: 10.1177/2050640617704564. Epub 2017 Apr 4.
Current guidelines recommend antibiotic prophylaxis in all patients presenting with cirrhosis and acute variceal hemorrhage (AVH). We aimed to evaluate the characteristics and clinical impact of "early" infections (developing within 14 days) of AVH in a real-world setting.
We analyzed retrospective data from a cohort of 371 adult patients with cirrhosis and AVH all of whom had received antibiotic prophylaxis (74% men; mean age 56 years), admitted to tertiary care hospitals in Edmonton, Alberta, Canada, and Barcelona, Spain. Sensitivity analyses were presented for culture-positive (confirmed) infections.
The mean MELD was 16. Fifty-two percent of patients received quinolones, 45% third-generation cephalosporins and 3% other antibiotics. Fourteen percent (51/371) developed an infection within 14 days of AVH. Seventy-five percent of infections were culture positive and occurred at a mean of six days from AVH. When all infections were considered, respiratory infections were the most common (53%) followed by urinary tract infections (17%) and bacteremia (16%). Resistance patterns differed between countries. Outpatient antibiotic prophylaxis (OR 5.4) and intubation (OR 2.6) were independent predictors of bacterial infection. Bacterial infection (OR 2.6) and the MELD (OR 1.2) were independent predictors of six-week mortality.
Early bacterial infections develop in 14% of cirrhotic patients with AVH despite antibiotic prophylaxis, and have a negative impact on six-week mortality. Intubation and outpatient antibiotic prophylaxis are associated with increased risk of early bacterial infections. Patients at risk should be followed closely with prompt infection workup and local antibiogram-based expansion of antibiotic therapy in case of clinical decline.
当前指南建议,所有肝硬化合并急性静脉曲张出血(AVH)的患者均应接受抗生素预防治疗。我们旨在评估在实际临床环境中,AVH患者“早期”(14天内发生)感染的特征及临床影响。
我们分析了来自加拿大艾伯塔省埃德蒙顿市和西班牙巴塞罗那市三级医院的371例肝硬化合并AVH成年患者队列的回顾性数据,所有患者均接受了抗生素预防治疗(74%为男性;平均年龄56岁)。对培养阳性(确诊)感染进行了敏感性分析。
平均终末期肝病模型(MELD)评分为16。52%的患者接受了喹诺酮类药物治疗,45%接受了第三代头孢菌素治疗,3%接受了其他抗生素治疗。14%(51/371)的患者在AVH发生后14天内发生了感染。75%的感染培养阳性,平均发生在AVH后6天。若考虑所有感染,呼吸道感染最为常见(53%),其次是尿路感染(17%)和菌血症(16%)。不同国家的耐药模式有所不同。门诊抗生素预防治疗(比值比[OR] 5.4)和插管(OR 2.6)是细菌感染的独立预测因素。细菌感染(OR 2.6)和MELD评分(OR 1.2)是6周死亡率的独立预测因素。
尽管进行了抗生素预防治疗,但仍有14%的肝硬化合并AVH患者会发生早期细菌感染,且对6周死亡率有负面影响。插管和门诊抗生素预防治疗与早期细菌感染风险增加相关。应对有风险的患者进行密切随访,一旦临床症状恶化,应迅速进行感染检查,并根据当地抗菌谱扩大抗生素治疗范围。